3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Stomach Neoplasms
1
Sarcoma
1
Noonan Syndrome 6
1
Neuroblastoma
1
Melanoma
1
Malignant Non-small Cell Neoplasm of Lung Stage IV
1
Lymphoproliferative Disorders
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Temozolomide
109
Magnetic Resonance Spectroscopy
52
Bevacizumab
52
Radiotherapy
44
Irinotecan
27
Blood Specimen Collection
19
Surgical Procedures, Operative
16
Radiation
15
Aminolevulinic Acid
15
Carboplatin
13
fluorodopa F 18
12
Nivolumab
12
Radiotherapy, Intensity-Modulated
11
Carmustine
11
Radiosurgery
10
Magnetic Resonance Imaging
10
pembrolizumab
9
Topotecan
9
Specimen Handling
9
Everolimus
9
Erlotinib Hydrochloride
9
Biopsy
9
poly ICLC
8
Surveys and Questionnaires
8
Standard of Care
8
Etoposide
8
Drug Therapy
8
Lomustine
7
Filgrastim
7
Cyclophosphamide
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Glioma
×
capmatinib
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled